These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 36749666)
21. Discovery of Highly Potent CRBN Ligands and Insight into Their Binding Mode through Molecular Docking and Molecular Dynamics Simulations. Yan J; Zheng Z ChemMedChem; 2023 Mar; 18(5):e202200573. PubMed ID: 36750890 [TBL] [Abstract][Full Text] [Related]
22. [Cereblon as a primary target of IMiDs]. Ito T; Handa H Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822 [TBL] [Abstract][Full Text] [Related]
23. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands. Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968 [TBL] [Abstract][Full Text] [Related]
25. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. Ishida T; Ciulli A SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537 [TBL] [Abstract][Full Text] [Related]
26. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH Science; 2018 Nov; 362(6414):. PubMed ID: 30385546 [TBL] [Abstract][Full Text] [Related]
27. Differential Analysis of Cereblon Neosubstrates in Rabbit Embryos Using Targeted Proteomics. Federspiel JD; Catlin NR; Nowland WS; Stethem CM; Mathialagan N; Fernandez Ocaña M; Bowman CJ Mol Cell Proteomics; 2024 Jul; 23(7):100797. PubMed ID: 38866076 [TBL] [Abstract][Full Text] [Related]
28. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008 [TBL] [Abstract][Full Text] [Related]
29. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579 [TBL] [Abstract][Full Text] [Related]
30. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720 [TBL] [Abstract][Full Text] [Related]
31. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment. Dann GP; Liu H; Nowak RP; Jones LH Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755 [TBL] [Abstract][Full Text] [Related]
32. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology. Ito T; Yamaguchi Y; Handa H Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753 [TBL] [Abstract][Full Text] [Related]
33. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151 [TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of thalidomide and its derivatives. Ito T; Handa H Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938 [TBL] [Abstract][Full Text] [Related]
35. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626 [TBL] [Abstract][Full Text] [Related]
36. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012 [TBL] [Abstract][Full Text] [Related]
37. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Petzold G; Fischer ES; Thomä NH Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs. Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128 [TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms of cereblon-based drugs. Asatsuma-Okumura T; Ito T; Handa H Pharmacol Ther; 2019 Oct; 202():132-139. PubMed ID: 31202702 [TBL] [Abstract][Full Text] [Related]
40. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]